Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent

PTC596 is an investigational small-molecule tubulin-binding agent. Unlike other tubulin-binding agents, PTC596 is orally bioavailable and is not a P-glycoprotein substrate. So as to characterize PTC596 to position the molecule for optimal clinical development, the interactions of PTC596 with tubulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jernigan, Finith, Branstrom, Arthur, Baird, John D., Cao, Liangxian, Dali, Mandar, Furia, Bansri, Kim, Min Jung, O'Keefe, Kylie, Kong, Ronald, Laskin, Oscar L., Colacino, Joseph M., Pykett, Mark, Mollin, Anna, Sheedy, Josephine, Dumble, Melissa, Moon, Young-Choon, Sheridan, Richard, Mühlethaler, Tobias, Spiegel, Robert J., Prota, Andrea E., Steinmetz, Michel O., Weetall, Marla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398121/
https://www.ncbi.nlm.nih.gov/pubmed/34315764
http://dx.doi.org/10.1158/1535-7163.MCT-20-0774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398121/
https://www.ncbi.nlm.nih.gov/pubmed/34315764
http://dx.doi.org/10.1158/1535-7163.MCT-20-0774

Ejemplares similares